Market Study on miRNA Sequencing: employment of newer approaches to extract the sequencing of miRNA to propel the market growth
Industry: Healthcare
Published Date: November-2022
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 250
Report ID: PMRREP33228
The newly released miRNA Sequencing and Assay Market analysis report by Persistence Market Research shows that global sales of the miRNA Sequencing and Assay Market in 2021 was held at US$ 227.7 Mn. With 18.1%, the projected market growth during 2022 - 2032 is expected to be significantly higher than the historical growth. Sequencing by Synthesis is expected to be the highest revenue-generating technology category, projected to register an opportunity of 20.8% CAGR 2022 – 2032.
|
Attributes |
Details |
|
Global miRNA Sequencing and Assay Market Size (2022) |
US$ 267.7 Mn |
|
Global miRNA Sequencing and Assay Market Size (2032) |
US$ 1.4 Bn |
|
Global miRNA Sequencing and Assay Market CAGR (2022-2032) |
18.1% |
|
U.S. miRNA Sequencing and Assay Market Size (2022) |
US$ 109 Mn |
|
Key Companies Covered |
|
As per the miRNA Sequencing and Assay Market research by Persistence Market Research, market research, and competitive intelligence provider, historically, from 2017 to 2021, market value of the miRNA Sequencing and Assay Market increased at around 16.2% CAGR.
Small RNA sequence analysis aids in the discovery of new miRNAs as well as other small RNAs, as well as the assessment of their differential expression in a sample. The approach is appropriate for analyzing microRNAs without previous intermediate structures or sequence information, as well as single-base resolution characterization of variants such as isomiRs. Furthermore, as the use of miRNA sequencing analysis grows, leading firms in the industry have made considerable expenditures.
The market is predicted to rise due to factors such as an increase in the frequency of infectious and communicable illnesses, technological advancements, and the employment of newer approaches to extract the sequencing of miRNA. The growing interest in miRNA biomarker identification might enhance the miRNA sequencing and testing business. Furthermore, market growth is due to factors such as an increase in the frequency of neurological illnesses and a rising demand for personalized treatments.
Which Region is projected to Offer the Largest Opportunity for the miRNA Sequencing and Assay Market?
North America is expected to account for the largest market at over 4% throughout the forecasted period. This is due to the presence of prominent firms in the region, including Illumina Inc., PerkinElmer, Inc., and Thermo Fisher Scientific among others. The key firms increased R&D expenditure in the United States to produce novel solutions. Illumina, Inc., for example, spent US$ 682 million on R&D in 2020 to create new sequence analysis technologies and enhance existing technology.
Due to the existence of organizations that are taking steps to teach researchers in this area, the market in the Asia Pacific is predicted to develop at the fastest rate throughout the forecast period. For example, APBioNet is an Asia Pacific informatics network that tracks the development of bioinformatics infrastructure, facilitates data and information sharing, and hosts training programs, seminars, and conferences.
U.S. miRNA Sequencing and Assay Market Analysis
The United States is expected to have the highest market share of US$ 556.3 Mn by the end of 2032. miRNA sequencing & assay market in this country is developing due to factors such as increased investments in sequencing development, growing research in the disciplines of Genomics and RNA biology, and a rising need for cost-effective, high-throughput approaches for miRNA analysis.
U.K. miRNA Sequencing and Assay Market Analysis
The miRNA Sequencing and Assay Market in the U.K. is expected to reach a valuation of US$ 58.3 Mn in 2032, growing from US$ 8.8 Mn in 2021. During the forecast period, the market is expected to gross an absolute dollar opportunity of US$ 48 Mn.
Japan miRNA Sequencing and Assay Market Analysis
In Japan, the miRNA Sequencing and Assay Market is expected to reach a valuation of US$ 62 Mn, rising from US$ 7.2 Mn in 2021. With a CAGR of 22%, the market in the country is projected to garner an absolute dollar opportunity of US$ 53 Mn during 2022 – 2032.
South Korea miRNA Sequencing and Assay Market Analysis
The miRNA Sequencing and Assay Market in South Korea is expected to reach US$ 24.3 Mn, rising from US$ 4.2 Mn in 2021. Growing at a CAGR of 17.1%, the market is projected to gross US$ 19 Mn absolute dollar opportunity during 2022 – 2032.
Which miRNA Sequencing and Assay Market is projected to Witness the Fastest Growth among the Component Types?
The product segment is forecasted to grow at the highest CAGR during 2022-2032. Illumina Inc., for example, provides a comprehensive suite of library preparation, sequence devices, accessories, consumables, software, and analytics for miRNA sequence analysis. Throughout the projected period, ongoing research to produce new products is anticipated to enhance sector market share.
Cold Spring Harbor Laboratory created BrumiR, an algorithm capable of discovering miRNAs directly and solely from sRNA-seq data. BrumiR was tested using datasets from animal and plant species, as well as actual and simulated sRNA-seq investigations. The results show that BrumiR has the greatest recollection for miRNA discovery while also being more efficient and more quickly than the current state-of-the-art methods.
Which miRNA Sequencing and Assay Market is projected to Witness the Fastest Growth among the Technology Type?
The sequencing by Synthesis (SBS) technology segment is forecasted to grow at the highest CAGR of 20.8% during 2022-2032. The continuous study and research in miRNA sequencing & assay by synthesizing is responsible for a substantial portion of the sector. Scientists from Germany, The United States, and China analyzed the conventional SBS and the approaches utilized for it in a January 2021 study. SBS retrieved more annotated miRNAs and created more new miRNAs, according to the findings.
SBS technology is also frequently used to analyze and investigate a variety of malignancies, as well as to develop tailored medicines. During the projected period, this is likely to account for a significant portion of the segment. SOLiD technology is noted for its accuracy, especially when such coverage is greater than 30x. As a result, it is widely employed in genetic recombination, transcriptome sequencing, and focused resequencing to detect changes. Currently, existing systems have 99.99% accuracy and a data source of 30 G for each run.
What is the impact of Covid-19 on the miRNA Sequencing and Assay Market?
During the Covid-19 outbreak, the researchers found that SARS-CoV-2 RNA sequences interacted with human MicroRNAs for developing a vaccine. MicroRNAs (miRNA) are a new and significant component of the virus-host cell interaction. Although it has been hypothesized that host miRNAs have an influence on SARS-CoV-2 infection. By crossing two luciferase-based reporter plasmids containing virus target sequences or their reversed sequences into the lungs A549 cell line, their contact with virus sequences was experimentally confirmed. The reporter plasmids reduced luciferase activity in five of the eight possible binding sites after transfection, indicating that they are sensitive to endogenously produced miRNAs.
Some of the key companies operating in the miRNA Sequencing and Assay Market are Thermo Fisher Scientific, Illumina, QIAGEN, PerkinElmer, Abcam plc, New England Biolabs, Takara Bio Inc., Lexogen GmbH, Norgen Biotek Corp, Maravai LifeSciences, HTG Molecular Diagnostics, Meridian Bioscience, Inc., and System Biosciences, LLC.
Some of the recent developments in the miRNA Sequencing and Assay Market are:
Similar recent developments related to companies in miRNA Sequencing and Assay Market are tracked by the team at Persistence Market Research, which are available in the full report.
By Component
By Technology
By Workflow
By Application
By Region
To know more about delivery timeline for this report Contact Sales
The global miRNA Sequencing and Assay Market is worth more than US$ 227.7 Mn at present.
The value of the miRNA Sequencing and Assay Market is projected to increase at a CAGR of around 18.1% during 2022 – 2032.
The value of the miRNA Sequencing and Assay Market increased at a CAGR of around 16.2% during 2017 – 2021.
The market for miRNA Sequencing and Assay Market in US is projected to expand at a CAGR of around 17.7% during 2022 – 2032.
